Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

Curevo Vaccine raises $110M Series B for shingles vaccine trial extension, adds Moncef Slaoui as board chair and Moderna's Tal Zaks to board. Aims to compete with GSK's Shingrix.

View Full Profile. Learn about our Editorial Policies. Moncef Slaoui, the former head of the US government’s COVID-19 vaccine initiative called Operation Warp Speed, has been fired from the Galvani ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024. “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are ...

Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment. In the space of 24 hours ...

Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo ...